To assess the impact of the pre-diagnostic use of corticosteroid on the prognosis of visual outcomes and treatment methods of fungal keratitis. Methods: This was a retrospective consecutive case cohort study. Two hundred and eleven eyes of 211 patients diagnosed with fungal keratitis from December 2014 to December 2015 in Shandong Eye Hospital were analyzed. Thirty-six eyes of 36 patients with a history of corticosteroid use before the diagnosis was the corticosteroid group. The remaining 175 eyes of 175 patients with no use of corticosteroid before or during the treatment was the control group. Patients' demographics, clinical findings, management details, changes after the antifungal therapy, and corrected distance visual acuity 2 months after the cure were recorded. Independent samples t test and chi-square test The fungal onset time of the corticosteroid group was 14.5±10.1 days, which was significantly shorter than that of the control group, 20.6±22.5 days (t=2.657, P=0.008). The mean diameter of corneal lesions was 6.3±2.4 mm in the corticosteroid group, which was significantly larger than that of the control group 4.8±2.1 mm (t=3.683, P<0.001). The positive rate of a corneal scrape was 97.2% in the corticosteroid group and 90.6% in the control group, with no significant difference between the groups (χ2 =1.633, P=0.201). Only 1 case (2.8%) in the corticosteroid group was cured by antifungal drugs, which was significantly lower than that of the control group, with 34 cases (19.4%) (χ2 =5.983, P=0.014). Penetrating keratoplasty was performed in 22 cases (61.1%) in the corticosteroid group, a proportion that was significantly higher than that in the control group, with 55 cases (31.4%) (χ2 =11.351, P=0.001). A corrected distance visual acuity of less than 0.3 after antifungal therapy was recorded in 32 cases (88.9%) in the corticosteroid group, a proportion which was significantly higher than in the control group, 110 cases (62.8%) (χ2 =9.194, P=0.002). Conclusions: Corticosteroid use before a diagnosis of fungal keratitis can increase the range of lesions, while antifungal drugs seem to be less effective, which increases the probability of penetrating keratoplasty and a poorer outcome. were used for statistical analysis. Results: The demographic data were matched between the two groups.
Sun CQ, Prajna NV, Krishnan T, et al. Effect of pretreatment with antifungal agents on clinical outcomes in fungal keratitis. Clin Exp Ophthalmol, 2016, 44(9): 763-767. DOI: 10.1111/ceo. 12794.
[2]
Wong TY, Ng TP, Fong KS, et al. Risk factors and clinical outcomes between fungal and bacterial keratitis: A comparative study. CLAO J, 1997, 23(4): 275-281.
[3]
Jurkunas U, Behlau I, Colby K. Fungal keratitis: Changing pathogens and risk factors. Cornea, 2009, 28(6): 638-643. DOI: 10.1097/ICO.0b013e318191695b.
[4]
Bharathi MJ, Ramakrishnan R, Meenakshi R, et al. Analysis of the risk factors predisposing to fungal, bacterial & Acanthamoeba keratitis in south India. Indian J Med Res, 2009, 130(6): 749-757.
[5]
Fernandes M, Vira D, Dey M, et al. Comparison between polymicrobial and fungal keratitis: Clinical features, risk factors, and outcome. Am J Ophthalmol, 2015, 160(5): 873-881.e2. DOI: 10.1016/j.ajo.2015.07.028.
[6]
Lalitha P, Prajna NV, Kabra A, et al. Risk factors for treatment outcome in fungal keratitis. Ophthalmology, 2006, 113(4): 526- 530. DOI: 10.1016/j.ophtha.2005.10.063.
[7]
Xu LJ, Song XS, Zhao J, et al. Hypopyon in patients with fungal keratitis. Chin Med J (Engl), 2012, 125(3): 470-475.
Henry CR, Flynn HW Jr, Miller D, et al. Infectious keratitis progressing to endophthalmitis: A 15-year study of microbiology, associated factors, and clinical outcomes. Ophthalmology, 2012, 119(12): 2443-2449. DOI: 10.1016/j.ophtha.2012.06.030.
[11]
Peixoto I, Maquine G, Francesconi VA, et al. Dermatophytosis caused by Tricophyton rubrum as an opportunistic infection in patients with Cushing disease. An Bras Dermatol, 2010, 85(6): 888-890.
Ledbetter EC, Irby NL, Kim SG. In vivo confocal microscopy of equine fungal keratitis. Vet Ophthalmol, 2011, 14(1): 1-9. DOI: 10.1111/j.1463-5224.2010.00822.x.
[14]
Shi W, Li S, Liu M, et al. Antifungal chemotherapy for fungal keratitis guided by in vivo confocal microscopy. Graefes Arch Clin Exp Ophthalmol, 2008, 246(4): 581-586. DOI: 10.1007/ s00417-007-0719-x.
Srinivasan M, Mascarenhas J, Rajaraman R, et al. Corticosteroids for bacterial keratitis: The Steroids for Corneal Ulcers Trial (SCUT). Arch Ophthalmol, 2012, 130(2): 143-150. DOI: 10.1001/archophthalmol.2011.315.
[17]
Srinivasan M, Mascarenhas J, Rajaraman R, et al. The Steroids for Corneal Ulcers Trial: Study design and baseline characteristics. Arch Ophthalmol, 2012, 130(2): 151-157. DOI: 10.1001/ archophthalmol.2011.303.
[18]
Ray KJ, Srinivasan M, Mascarenhas J, et al. Early addition of topical corticosteroids in the treatment of bacterial keratitis. JAMA Ophthalmol, 2014, 132(6): 737-741. DOI: 10.1001/ jamaophthalmol.2014.292.
[19]
Srinivasan M, Mascarenhas J, Rajaraman R, et al. The steroids for corneal ulcers trial (SCUT): Secondary 12-month clinical outcomes of a randomized controlled trial. Am J Ophthalmol, 2014, 157(2): 327-333.e3. DOI: 10.1016/j.ajo.2013.09.025.
[20]
Robaei D, Carnt N, Minassian DC, et al. The impact of topical corticosteroid use before diagnosis on the outcome of Acanthamoeba keratitis. Ophthalmology, 2014, 121(7): 1383- 1388. DOI: 10.1016/j.ophtha.2014.01.031.
[21]
Nielsen SE, Nielsen E, Julian HO, et al. Incidence and clinical characteristics of fungal keratitis in a Danish population from 2000 to 2013. Acta Ophthalmol, 2015, 93(1): 54-58. DOI: 10.1111/aos.12440.
[22]
Rogers GM, Goins KM, Sutphin JE, et al. Outcomes of treatment of fungal keratitis at the University of Iowa Hospitals and Clinics: A 10-year retrospective analysis. Cornea, 2013, 32(8): 1131-1136. DOI: 10.1097/ICO.0b013e3182883e9d.
[23]
Mohd-Tahir F, Norhayati A, Siti-Raihan I, et al. A 5-year retrospective review of fungal keratitis at hospital universiti sains malaysia. Interdiscip Perspect Infect Dis, 2012, 2012: 851563. DOI: 10.1155/2012/851563.
[24]
Shimazaki J, Iseda A, Satake Y, et al. Efficacy and safety of long-term corticosteroid eye drops after penetrating keratoplasty: A prospective, randomized, clinical trial. Ophthalmology, 2012, 119(4): 668-673. DOI: 10.1016/j.ophtha.2011.10.016.
[25]
Nguyen NX, Seitz B, Martus P, et al. Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty. Am J Ophthalmol, 2007, 144(2): 318- 319. DOI: 10.1016/j.ajo.2007.03.028.
[26]
Das M, Murthy SI, Dikshit S, et al. Natamycin and voriconazole in fungal keratitis. Arch Ophthalmol, 2011, 129(6): 814; author reply 814-815. DOI: 10.1001/archophthalmol.2011.97.
[27]
Prajna NV, O'Brien KS, Acharya NR, et al. Voriconazole for fungal keratitis. Ophthalmology, 2013, 120(9): e62-63. DOI: 10.1016/j.ophtha.2013.06.016.
[28]
王丽娅, 许中中, 张俊杰, 等. 局部应用伏立康唑治疗真菌
性角膜炎的临床观察. 中华眼科杂志, 2016, 52(9): 657-662.
DOI: 10.3760/cma.j.issn.0412-4081.2016.09.005.
[29]
Gong H, Gong X. Combined application of 5% natamycin and 0.2% fluconazole for the treatment of fungal keratitis. Eye Sci, 2013, 28(2): 84-87.
[30]
Qiu S, Zhao GQ, Lin J, et al. Natamycin in the treatment of fungal keratitis: A systematic review and Meta-analysis. Int J Ophthalmol, 2015, 8(3): 597-602. DOI: 10.3980/j.issn.2222- 3959.2015.03.29.
Sun JP, Chen WL, Huang JY, et al. Microbial keratitis after penetrating keratoplasty. Am J Ophthalmol, 2017, 178: 150-156. DOI: 10.1016/j.ajo.2017.03.022.
[33]
Nanavaty MA. Unveiling opacification of intraocular lens following a successful penetrating keratoplasty for extensively scarred cornea due to microbial keratitis after Descemet's stripping automated endothelial keratoplasty. Indian J Ophthalmol, 2018, 66(5): 696. DOI: 10.4103/ijo.IJO_1253_17.
[34]
Liu Y, Jia H, Shi X, et al. Minimal trephination penetrating keratoplasty for severe fungal keratitis complicated with hypopyon. Can J Ophthalmol, 2013, 48(6): 529-534. DOI: 10.1016/j.jcjo.2013.05.017.
[35]
Shi W, Wang T, Xie L, et al. Risk factors, clinical features, and outcomes of recurrent fungal keratitis after corneal transplantation. Ophthalmology, 2010, 117(5): 890-896. DOI: 10.1016/j.ophtha.2009.10.004.